Merck disputed the British weekly, Lancet, that Vioxx should have been recalled four years earlier. Merck is the subject of a Justice Department criminal investigation and an SEC inquiry. The company's shares slumped on that news. The New York state pension fund filed a lawsuit against Merck. Nearly a year before Merck received results of the clinical trial prompting recall of Vioxx, patient records indicated the drug posed a cardiovascular risk. A drug safety expert at FDA accused the agency of pressing him to withhold a study showing the dangers of Vioxx. Merck has adopted large severance packages for executives. 